News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nora Therapeutics Presents Phase 1 Data On NT100 At The European Society Of Human Reproduction And Embryology Annual Meeting


6/30/2014 7:50:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PALO ALTO, Calif., June 30, 2014 (GLOBE NEWSWIRE) -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced the presentation of Phase 1 data on the safety and tolerability of its lead compound NT100, a novel rhG-CSF being developed for use in repeat implantation failure and recurrent miscarriage. The data will be presented at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting to be held from June 29 to July 2 in Munich, Germany.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES